N/A N=44 A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Alport Syndrome · Kidney Disease
Primary: Number of Subjects Developing Microalbuminuria During Study Period — 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=317 Obstructive Sleep Apnea in World Trade Center Responders
Obstructive Sleep Apnea
Primary: Adherence to CPAP Pre-crossover — 1; 0.89 Hours/night
Phase 2 N=30 Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
HIV-2 Infection
Primary: Percentage of Participants in Therapeutic Success — 40 percentage of participants
N/A N=68 Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers
Kidney Failure, Chronic · Eye Diseases · Diabetic Retinopathy
Primary: Usability of the RetinaVue Hand-Held 100 Camera — 20; 116 Retinal Images
Phase 2 N=15 Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) — 1200 dose in mg/m^2
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Phase 3 N=80 Japanese IP-TN Trial
Pain
Primary: Percentage of Patients With Drug-related Adverse Events [AEs] — 7.5 Percentage of participants
Phase 2 N=16 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Cervical Cancer · Precancerous Condition
Primary: Safety and Toxicity — 0; 0; 0 Participants
Phase 2 N=30 Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting
Nausea · Vomiting
Primary: Efficacy for the Prevention/Rescue of Radiation-induced Nausea and Vomiting. — 21; 4; 2; 0 Participants
Early Phase 1 N=9 A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Prostate Cancer
Primary: The Proportion of mCRPC Patients Treated With Vismodegib Who Achieve a Pharmacodynamic (PD) Response in Tumor Biopsies — 7 Participants
Phase 2 N=551 A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen
Rhinitis · Allergic · Seasonal
Primary: Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I — -3.80; -7.15; -7.05; -7.93 units on a scale — p=<0.001
Phase 3 N=120 Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
Epilepsy · Dravet Syndrome
Primary: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period — -38.94; -13.29 percent change — p=0.0123
N/A N=206 Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo
Ischemic Stroke
Primary: Weighted Modified Rankin Scale (mRS) Score, Lead Co-Primary Efficacy Outcome — 5.5; 3.4 score on a scale
N/A N=68 Exposure Therapy For Veterans With PTSD And Panic Attacks
PTSD · Panic Attacks
Primary: Change in PTSD Symptoms (CAPS) Between MCET-V and CPT Groups — 81.8; 80.5; 67.8; 68.1 units on a scale — p=0.30
Phase 2 N=34 A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
Epilepsy · Dravet Syndrome
Primary: Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 0; 1 Participants